Profile Response Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

Molecular Profile CD274 positive
Therapy Capecitabine + HX008 + Oxaliplatin
Indication/Tumor Type gastroesophageal junction adenocarcinoma
Response Type not predictive


  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")


  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
CD274 positive gastroesophageal junction adenocarcinoma not predictive Capecitabine + HX008 + Oxaliplatin Phase I Actionable In a Phase Ib trial, treatment with HX008, Xeloda (capecitabine), and Eloxatin (oxaliplatin) combination therapy resulted in an objective response rate (ORR) of 75% (9/12) and disease control rate (DCR) of 83.3% (10/12) in CD274 (PD-L1)-positive gastric or gastroesophageal junction cancer patients, compared to an ORR and DCR of 66.7% (6/9) and 100% (9/9) respectively in CD274 (PD-L1)-negative patients; however, no difference was observed in progression-free survival (p=0.19) (PMID: 33457083). 33457083
PubMed Id Reference Title Details
(33457083) Anti-PD-1 antibody HX008 combined with oxaliplatin plus capecitabine for advanced gastric or esophagogastric junction cancer: a multicenter, single-arm, open-label, phase Ib trial. Full reference...